- Home
- LSTA vs ACCS Comparison
LSTA vs ACCS Comparison
Compare LSTA & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | ACCS |
|---|---|---|
| Founded | 1980 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 13.6M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LSTA | ACCS |
|---|---|---|
| Price | $1.20 | $3.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 108.7K | 14.0K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.42 | ★ 139.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | $22,619,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.96 | $3.21 |
| 52 Week High | $5.07 | $11.34 |
Technical Indicators
Market Signals| Indicator | LSTA | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 35.49 |
| Support Level | $1.23 | $3.21 |
| Resistance Level | $1.28 | $5.11 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 56.18 | 37.11 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.